Sarcoma de Kaposi asociado a corticoterapia sistémica

González‐Sixto, B.; Conde, Alberto; Mayo, Eugenia; Pardavila, R.; Torre, Carlos de la; Cruces, Manuel

doi:10.1016/s0001-7310(07)70132-1

Cited by 18 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The iatrogenic form of KS, due to immunosuppression, is typically associated with the use of immunosuppressive therapy in organ transplant recipients (particularly kidney transplants). It can also occur in patients receiving immunosuppressive treatments for proliferative disorders/malignant processes or immune-mediated diseases [4,6,14,15] as well as the use of oral corticosteroids and other immunosuppressive agents [6,16,17], with KS appearing usually about a year after the first administration of the drugs in these cases. Here we report a case, which according to our knowledge from the review of literature, could be only the second reported case of Kaposi sarcoma following treatment for ALL, occurring outside the setting of a transplant, and the first with iatrogenic KS developing just over 2 years of ALL diagnosis in a child.…”

Section: Discussionmentioning

confidence: 99%

Oral–visceral iatrogenic Kaposi sarcoma following treatment for acute lymphoblastic leukemia: a case report and review of the literature

et al. 2022

View full text Add to dashboard Cite

Background There have hardly been any reported cases of children presenting with Kaposi sarcoma as a second malignancy following treatment for acute lymphoblastic leukemia outside a transplant setting. Case presentation We report a case of a 5-year-old boy of Bantu origin, which, to our knowledge, could be only the second reported case of oral–visceral Kaposi sarcoma after acute lymphoblastic leukemia treatment. The patient presented with a 1-month history of progressive, non-painful, soft tissue oral mass, 1 month after completing treatment for high-risk acute lymphoblastic leukemia. He was successfully treated for Kaposi sarcoma on a two-drug regimen (bleomycin and vincristine) with good clinical response. Conclusion Visceral Kaposi sarcoma as a second malignancy may occur after pediatric acute lymphoblastic leukemia treatment, but its rarity makes it unlikely to raise suspicion among clinicians, thus precluding early diagnosis and treatment. We recommend routine evaluation for Kaposi sarcoma lesions in children undergoing long-term surveillance following treatment for childhood acute leukemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral–visceral iatrogenic Kaposi sarcoma following treatment for acute lymphoblastic leukemia: a case report and review of the literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…El SK es un tumor vascular maligno que se conoce fundamentalmente por aparecer como complicación del síndrome de inmunodeficiencia adquirida (SK epidémico), pero puede asociarse también a tratamientos inmunosupresores (SK iatrogénico), habiéndose descrito casos asociados al tratamiento con corticoides en arteritis de la temporal1, 2, 3. No existe un consenso para el tratamiento óptimo de este tumor, variando desde la observación a un tratamiento tópico o sistémico dependiendo de varios factores 4 .…”

unclassified

“…No existe un consenso para el tratamiento óptimo de este tumor, variando desde la observación a un tratamiento tópico o sistémico dependiendo de varios factores 4 . Los corticoides podrían actuar como inductores o desencadenantes de la enfermedad 1 , lo que explicaría que no siempre se resuelva al suspenderse dicho tratamiento.…”

unclassified